Impact of the COVID-19 pandemic on antibiotic treatment for respiratory tract infections in Norwegian primary care.

backgroundDuring the COVID-19 pandemic, the use of macrolides, specifically azithromycin, for respiratory tract infections (RTIs) in primary care increased in several countries. In Norway, antibiotic treatment of COVID-19 was never recommended.

objectivesTo investigate the antibiotic treatment for RTIs in Norwegian primary care, comparing pre-pandemic and pandemic periods.

methodsWe defined RTI episodes and antibiotic treatment using several national registries including demographic and residency data from Statistics Norway, reimbursement claims from the Norwegian Registry for Primary Health Care, antibiotic dispensing from the Norwegian Prescription Database, and deaths from the Norwegian Cause of Death Registry, for the years 2018-2021.

resultsApproximately 80% of the 4 904 376 total RTI episodes during the study period were handled exclusively in daytime general practice (DGP). Use of electronic consultations for RTI episodes increased from less than 1% to more than 50%. Throughout the study period, most RTI episodes were handled without antibiotic use. The antibiotic treatment rate for RTI episodes dropped during the pandemic, relative risk (RR) 0.52, 95% confidence interval (CI) 0.52-0.52, compared to pre-pandemic. Over half of all antibiotic treatments for RTIs were phenoxymethylpenicillin, and the distribution of antibiotic types was relatively stable during the study period, except for some temporary changes in the initial months of the pandemic. DGP handled most of the influx of RTIs during the first month of the COVID-19 pandemic in primary care, without increasing antibiotic use.

conclusionsDGP